Select a State

Global health R&D delivers for Colorado

US government investment in global health R&D has delivered

$93.8 million
to Colorado research institutions
1,400+ new jobs
for Colorado

Neglected diseases in Colorado

Chikungunya cases
25
Dengue cases
43
HIV diagnoses
3,491
Malaria cases
199
Tuberculosis cases
668
West Nile cases
1,083
Zika cases
61

Colorado's top USG-funded global health R&D institutions

Colorado State University
$58.3 million
University of Colorado at Denver
$27.2 million
University of Colorado at Boulder
$5.8 million
Precision Photonics Corporation (now part of IDEX Corporation)
$1.4 million
Colorado School of Mines
$1.0 million
Keystone Symposia on Molecular and Cellular Biology
$88 thousand

Colorado industry in global health R&D

AstraZeneca
Location(s):
Boulder
Endolytics
Location(s):
Fort Collins
IDEX Corporation
Location(s):
Denver
Mbio
Location(s):
Boulder
Novartis
Location(s):
Broomfield
Sandoz
Location(s):
Broomfield
SomaLogic
Location(s):
Boulder

Colorado's top areas of global health R&D by USG funding

11.5%
HIV/AIDS
5.5%
Malaria
48.3%
Tuberculosis
2.7%
Diarrheal diseases
7.8%
Salmonella infections
19.7%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
4.5%
Other
Bacteria pneumonia & meningitis
Non-allocable

Global health R&D at work in Colorado

University of Colorado School of Medicine researchers discovered that a process that protects the body from autoimmune disease also blocks the production of antibodies against HIV-1, the most common cause of AIDS. The immune system normally suppresses these antibodies to keep them from targeting healthy tissues; the question now is whether temporarily halting this mechanism would allow generation of antibodies capable of neutralizing HIV-1 without harm to patients. The findings could help scientists develop a vaccine.

Footnotes